Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
AC Immune SA ( (ACIU) ) has issued an announcement.
AC Immune SA announced key executive promotions effective January 1, 2025, as part of its strategic succession planning to enhance its Research and Development operations. The appointments include Mark Danton as Executive Vice President, reflecting the growing significance of AI and digital technologies; Dr. Günther Staffler as Senior Vice President of Immunotherapy, following his work on the ACI-7104.056 immunotherapy candidate; and Dr. Francesca Capotosti as Vice President of Research, noted for her contributions to small molecule therapeutic programs. These leadership changes aim to bolster the company’s market position in neurodegenerative disease treatment.
More about AC Immune SA
AC Immune SA is a biotechnology company based in Lausanne, Switzerland, specializing in the development of innovative medicines for neurodegenerative diseases. The company focuses on immunotherapies and small molecule therapies, with a significant emphasis on targeting proteins like Tau and alpha-synuclein for therapeutic and diagnostic purposes.
YTD Price Performance: -41.60%
Average Trading Volume: 113,569
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $293.1M
See more insights into ACIU stock on TipRanks’ Stock Analysis page.
